Cervical
The development of the HPV vaccine and enhanced screening techniques like liquid-based cytology have drastically reduced the incidence and mortality rates of cervical cancer worldwide.
Treatment advances across the cervical cancer spectrum – Nature Reviews Clinical Oncology
In this Review, the authors discuss key clinical trials and therapeutic advances that have informed the current treatment landscape for cervical cancers of all stages, including refinement of surgical management approaches, the establishment of chemoradiotherapy, and the integration of anti-angiogenic agents, immune-checkpoint inhibitors and antibody–drug conjugates.
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer – Genmab (NASDAQ:GMAB) – Benzinga
Japan approves Tivdak, the first ADC for cervical cancer, after Phase 3 trial shows a 30% reduction in death risk vs. chemotherapy.
CDC report adds to evidence that HPV vaccine is preventing cervical cancer in US women
A new government report adds to evidence that the HPV vaccine, once called dangerous by Health and Human Services Secretary Robert F. Kennedy Jr., is preventing cervical cancer in young women.
Cancer breakthrough: New jab could slash risk of cervical cancer
More than half of those given a new vaccine in a clinical trial saw their pre-cancerous cells destroyed
Zai Lab stock rises on Tivdak trial data (ZLAB:NASDAQ) | Seeking Alpha
Zai Lab (ZLAB) stock rose after positive trial data for its cervical cancer drug Tivdak and its plans to seek marketing approval for the drug in China. Read more here.
The elimination of cervical cancer in NZ is within reach—but not without funding and a plan
After committing to a global plan to eliminate cervical cancer, New Zealand is lagging behind Australia and other countries in how it manages this preventable disease.
